| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.008 | 0.9 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |